Skin of Color pp 161-179 | Cite as

Disorders of Hypopigmentation and Depigmentation

  • Ife J. Rodney
  • Rebat M. Halder


Disorders of hypopigmentation and depigmentation are of great concern to patients of skin of color because of the marked contrast between the affected skin and normal skin. These disorders can be psychologically devastating in this patient group. There are a number of disorders of hypopigmentation and depigmentation that are clinically relevant. Those that will be discussed in this chapter are idiopathic guttate hypomelanosis, pityriasis alba, progressive macular hypomelanosis, postinflammatory hypopigmentation, oculocutaneous albinism 2B, piebaldism, and vitiligo.


Topical Corticosteroid Seborrheic Dermatitis Pityriasis Versicolor Oculocutaneous Albinism Hypopigmented Macule 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Falabella R. Idiopathic guttate hypomelanosis. Dermatologic Clin. 1988;6(2):241–7.Google Scholar
  2. 2.
    Falabella R, Escobar C, Giraldo N, Rovetto P, Gil J, Barona MI, Acosta F, Alzate A. On the pathogenesis of idiopathic guttate hypomelanosis. J Am Acad Dermatol. 1987;16(pt 1):35–44.PubMedCrossRefGoogle Scholar
  3. 3.
    Ortonne JP, Perrot H. Idiopathic guttate hypomelanosis. Arch Dermatol. 1980;116:664–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Cummings KI, Cottel WI. Idiopathic guttate hypomelanosis. Arch Dermatol. 1966;93:184.PubMedCrossRefGoogle Scholar
  5. 5.
    Bolognia J, Pawelek J. Biology of hypopigmentation. J Am Acad Dermatol. 1988;19:217–55.PubMedCrossRefGoogle Scholar
  6. 6.
    Wallace ML, Grichnik JM, Prieto VG, et al. Numbers and differentiation status of melanocytes in idiopathic guttate hypomelanosis. J Cutan Pathol. 1998;25:375–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Kaya TI, Yazici AC, Tursen U, Ikizoglu G. Idiopatihic guttate hypomelanosis: idiopathic or ultraviolet induced? Photodermatol Photoimmunol Photomed. 2005;21:270–1.PubMedCrossRefGoogle Scholar
  8. 8.
    Golhar A, Pillar T, Eidelman S, Etzioni A. Vitiligo and idiopathic guttate hypomelanosis. Repigmentation of skin following engraftment onto nude mice. Arch Dermatol. 1989;125(10): 1363–6.CrossRefGoogle Scholar
  9. 9.
    Ploysangam T, Dee-Ananlap S, Suvanprakorn P. Treatment of idiopathic guttate hypomelanosis with liquid nitrogen: light and electron microscopic studies. J Am Acad Dermatol. 1990;23(4 Pt 1):681–4.PubMedCrossRefGoogle Scholar
  10. 10.
    Hexsel DM. Treatment of idiopathic guttate hypomelanosis by localized superficial dermabrasion. Dermatol Surg. 1999;25(11):917–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Kumarasinghe SP. 3-5 second cryotherapy is effective in idiopathic guttate hypomelanosis. J Dermatol. 2004;31(5):437–9.PubMedGoogle Scholar
  12. 12.
    Fox H. Partial depigmentation: chiefly on the face in Negro children. Arch Dermatol Syphilol. 1923;7:268–9.Google Scholar
  13. 13.
    O’Farrell MM. Pityriasis alba. Arch Dermatol. 1956;73:376–8.CrossRefGoogle Scholar
  14. 14.
    Halder RM. Pigmentary disorders in pigmented skins. In: Halder RM, editor. Dermatology and dermatological therapy of pigmented skins. Boca Raton: Taylor and Francis; 2006.Google Scholar
  15. 15.
    Watkins DB. Pityriasis alba: a form of atopic dermatitis. A preliminary report. Arch Dermatol. 1961;83:915–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Diepgen TL, Fartasch M, Hornstein OP. Evaluation and relevance of atopic basic and minor features in patients with atopic dermatitis and in the general population. Acta Derm Venereol Suppl (Stockh). 1989;144:50–4.Google Scholar
  17. 17.
    Bassaly M, Miale Jr A, Prasad AS. Studies on pityriasis alba: a common facial skin lesion in Egyptian children. Arch Dermatol. 1963;88:272–5.PubMedCrossRefGoogle Scholar
  18. 18.
    Martin RF, Lugo-Somolinos A, Sanchez JL. Clinicopathologic study on pityriasis alba. Bol Asoc Med PR. 1990;82:463–5.Google Scholar
  19. 19.
    Zaynoun ST, Aftimos BG, Tenekjian KK, et al. Extensive pityriasis alba: a histological, histochemical and ultrastructural study. Br J Dermatol. 1983;108:83–90.PubMedCrossRefGoogle Scholar
  20. 20.
    Blessmann Weber M, Sponchiado deAvila LG, Albaneze R, et al. Pityriasis alba: a study of pathogenic factors. J Eur Acad Dermatol Venereol. 2002;16:463–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Urano-Suehisa S, Tagami H. Functional and morphological analysis of the horny layer of pityriasis alba. Acta Derm Venereol. 1985;65:164–7.PubMedGoogle Scholar
  22. 22.
    Wells BT, Whyte HJ, Kierland RR. Pityriasis alba: a ten year survey and review of the literature. Arch Dermatol. 1960;82:183–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Galan EB, Janniger CK. Pityriasis alba. Cutis. 1998;61:11–3.PubMedGoogle Scholar
  24. 24.
    Galadari E, Helmy M, Ahmed M. Trace elements in serum of pityriasis alba patients. Int J Dermatol. 1992;31:525–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Zaynoun S, Jaber LA, Kurban AK. Oral methoxsalen photochemotherapy of extensive pityriasis alba. Preliminary report. J Am Acad Dermatol. 1986;15:61–5.PubMedCrossRefGoogle Scholar
  26. 26.
    Dhar S, Kanwar AJ, Dawn G. Pigmenting pityriasis alba. Pediatr Dermatol. 1995;12:197–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Shah AS, Supapannachart N, Nordlund JJ. Acquired hypomelanotic disorders. In: Levine N, editor. Pigmentation and pigmentary disorders. Boca Raton: CRC Press; 1993. p. 352–3.Google Scholar
  28. 28.
    Zaynoun ST, Aftimos BG, Tenekjian KK, Bahuth N, Kurban AK. Extensive pityriasis alba: a histological, histochemical and ultrastructural study. Br J Dermatol. 1983;108:83–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Lin A. Topical immunotherapy. In: Wolverton SE, editor. Comprehensive dermatological therapy. Philadelphia: Saunders; 2001. p. 617–9.Google Scholar
  30. 30.
    Relyveld GN, Menke HE, Westerhof W. Progressive macular hypomelanosis: an overview. Am J Clin Dermatol. 2007;8(1):13–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Westerhof W, Relyveld GN, Kingswijk M, et al. Propionibacterium acnes and the pathogenesis of progressive macular hypomelanosis. Arch Dermatol. 2004;140:210–4.PubMedCrossRefGoogle Scholar
  32. 32.
    Di Lernia V, Ricci C. Progressive and extensive hypomelanosis and extensive pityriasis alba: same disease, different names? J Eur Acad Dermatol Venereol. 2005;19:370–2.PubMedCrossRefGoogle Scholar
  33. 33.
    Relyveld G, Menke H, Westerhof W. Letter to the editor: progressive and extensive hypomelanosis and extensive pityriasis alba: same disease, different names? J Eur Acad Dermatol Venereol. 2006;20(10):1363–4.PubMedCrossRefGoogle Scholar
  34. 34.
    Guillet G, Helenon R, Gauthier Y, et al. Progressive macular hypomelanosis of the trunk: primary acquired hypopigmentation. J Cutan Pathol. 1988;15:286–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Guillet G, Helenon R, Guillet MH, et al. Hypomelanose maculeuse confluente et progressive du metis melanoderme. Ann Dermatol Venereol. 1992;119(1):19–24.PubMedGoogle Scholar
  36. 36.
    Menke HE, Ossekoppele R, Dekker SK, et al. Nummulaire en confluerende hypomelanosis van de romp. Ned Tijdsch Dermatol Venereol. 1997;7:117–22.Google Scholar
  37. 37.
    Relyveld GN, Kingswijk M, Reitsma JB, et al. Benzoyl peroxide/clindamycin/ultraviolet A is more effective than fluticasone/ultraviolet A in progressive macular hypomelanosis: a randomized study. J Am Acad Dermatol. 2006;55(5):836–43.PubMedCrossRefGoogle Scholar
  38. 38.
    Morelli JG, Norris DA. Influence of inflammatory mediators and cytokines on human melanocyte function. J Invest Dermatol. 1993;100(2):191S–5. Review. PubMed PMID: 8381839.PubMedCrossRefGoogle Scholar
  39. 39.
    Grover R, Morgan BD. Management of hypopigmentation following burn injury. Burns. 1996;22(8):627–30. Review. PubMed PMID: 8982542.PubMedCrossRefGoogle Scholar
  40. 40.
    Ellis DA, Tan AK. How we do it: management of facial hyperpigmentation. J Otolaryngol. 1997;26(4):286–9.PubMedGoogle Scholar
  41. 41.
    Johnston GA, Sviland L, McLelland J. Melasma of the arms associated with hormone replacement therapy. Br J Dermatol. 1998;139(5):932.PubMedCrossRefGoogle Scholar
  42. 42.
    Passeron T, Mantoux F, Ortonne JP. Genetic disorders of pigmentation. Clin Dermatol. 2005;23:56–67.PubMedCrossRefGoogle Scholar
  43. 43.
    Witkop Jr CJ, Hill CW, Desnick S, Theis JK, Thorn HL, Jenkins M. Ophthalmologic, biochemical, platelet and ultrastructural defects in the various types of oculocutaneous albinism. J Invest Dermatol. 1973;60:443–56.PubMedCrossRefGoogle Scholar
  44. 44.
    Toyofuku K, Wada I, Spritz RA, Hearing VJ. The molecular basis of oculocutaneous albinism type 1 (OCA1): sorting failure and degradation of mutant tyrosinases results in a lack of pigmentation. Biochem J. 2001;355:259–69.PubMedCrossRefGoogle Scholar
  45. 45.
    Brilliant MH. The mouse p (pink-eyed dilution) and human P genes, oculocutaneous albinism type 2 (OCA2), and melanosomal pH. Pigment Cell Res. 2001;14:86–93.PubMedCrossRefGoogle Scholar
  46. 46.
    Rinchik EM, Bultman SJ, Horsthemke B, Lee ST, Strunk KM, Spritz RA, Avidano KM, Jong MTC, Nicholls RD. A gene for the mouse pink-eyed dilution locus and for human type II oculocutaneous albinism. Nature. 1993;361:72–6.PubMedCrossRefGoogle Scholar
  47. 47.
    Lee ST, Nicholls RD, Bundey S, Laxova R, Musarella M, Spritz RA. Mutations of the P gene in oculocutaneous albinism, ocular albinism, and Prader-Willi syndrome plus albinism. N Engl J Med. 1994;330:529–34.PubMedCrossRefGoogle Scholar
  48. 48.
    Rosemblat S, Sviderskaya EV, Easty DJ, Wilson A, Kwon BS, Bennett DC, Orlow SJ. Melanosomal defects in melanocytes from mice lacking expression of the pink-eyed dilution gene: correction by culture in the presence of excess tyrosine. Exp Cell Res. 1998;239:344–52.PubMedCrossRefGoogle Scholar
  49. 49.
    Puri N, Gardner JM, Brilliant MH. Aberrant pH of melanosomes in pink-eyed dilution (p) mutant melanocytes. J Invest Dermatol. 2000;115:607–13.PubMedCrossRefGoogle Scholar
  50. 50.
    Manga P, Orlow SJ. Inverse correlation between pink-eyed dilution protein expression and induction of melanogenesis by bafilomycin A1. Pigment Cell Res. 2001;14:362–7.PubMedCrossRefGoogle Scholar
  51. 51.
    Chen K, Manga P, Orlow SJ. Pink-eyed dilution protein controls the processing of tyrosinase. Mol Biol Cell. 2002;13:1953–64.PubMedCrossRefGoogle Scholar
  52. 52.
    Staleva L, Manga P, Orlow SJ. The pink-eyed dilution gene product controls arsenic sensitivity and cellular glutathione metabolism. Mol Biol Cell. 2002;13:4206–20.PubMedCrossRefGoogle Scholar
  53. 53.
    Toyofuku K, Valencia JC, Kushimoto T, et al. The etiology of oculocutaneous albinism (OCA) type II: the pink protein modulates the processing and transport of tyrosinase. Pigment Cell Res. 2002;15:217–24.PubMedCrossRefGoogle Scholar
  54. 54.
    Spritz RA. The molecular basis of human piebaldism. Pigment Cell Res. 1992;5:340–3.PubMedCrossRefGoogle Scholar
  55. 55.
    Sarangarajan R, Boissy RE. Tyrp1 and oculocutaneous albinism type 3. Pigment Cell Res. 2001;14:437–44.PubMedCrossRefGoogle Scholar
  56. 56.
    Newton JM, Cohen-Barak O, Hagiwara N, et al. Mutations in the human orthologue of the mouse underwhite gene (uw) underlie a new form of oculocutaneous albinism, OCA4. Am J Hum Genet. 2001;69:981–8.PubMedCrossRefGoogle Scholar
  57. 57.
    Okoro AN. Albinism in Nigeria. Br J Dermatol. 1975;92:485–92.PubMedCrossRefGoogle Scholar
  58. 58.
    Witkop CJ, Jr, Quevedo WC, Jr, Fitzpatrick TB, King RA. Albinism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic basis of inherited disease. 6th ed. Vol. 2. New York: McGraw-Hill; 1989. pp. 2905–2947.Google Scholar
  59. 59.
    Bothwell JE. Pigmented skin lesions in tyrosinase-positive oculocutaneous albinos: a study in black South Africans. Int J Dermatol. 1997;36(11):831–6.PubMedCrossRefGoogle Scholar
  60. 60.
    Kromberg JGR, Castle D, Zwane EM, Jenkins T. Albinism and skin cancer in Southern Africa. Clin Genet. 1989;36:43–52.PubMedCrossRefGoogle Scholar
  61. 61.
    Perry PK, Silverberg NB. Cutaneous malignancy in albinism. Cutis. 2001;67(5):427–30.PubMedGoogle Scholar
  62. 62.
    Ward KA, Moss C, Sanders DS. Human piebaldism: relationship between phenotype and site of kit gene mutation. Br J Dermatol. 1995;132:929–35.PubMedCrossRefGoogle Scholar
  63. 63.
    Thomas I, Kihiczac GG, Fox MD, et al. Piebaldism: an update. Int J Dermatol. 2004;43: 716–9.PubMedCrossRefGoogle Scholar
  64. 64.
    Mahakrishnan A, Srinivasan MS. Piebaldism with Hirschprung’s disease. Arch Dermatol. 1980;116:1102.PubMedCrossRefGoogle Scholar
  65. 65.
    Angelo C, Cianchini G, Grosso MG, et al. Association of piebaldism and neurofibromatosis type 1 in a girl. Pediatr Dermatol. 2001;18:490–3.PubMedCrossRefGoogle Scholar
  66. 66.
    Kiwan RA, Mutasim DF. Grover disease (transient acantholytic dermatosis) and piebaldism. Cutis. 2002;69:451–3.PubMedGoogle Scholar
  67. 67.
    Spritz RA, Beighton P. Piebaldism with deafness: molecular evidence for an expanded ­syndrome. Am J Med Genet. 1998;75:101–3.PubMedCrossRefGoogle Scholar
  68. 68.
    Ezoe K, Holmes SA, Ho L, et al. Novel mutations and deletions of the KIT (steel factor receptor) gene in human piebaldism. Am J Hum Genet. 1995;56:58–66.PubMedGoogle Scholar
  69. 69.
    Sanchez-Martin M, Perez-Losada J, Rodriguez-Garcia A, et al. Deletion of the SLUG(SNAI2) gene results in human piebaldism. Am J Med Genet A. 2003;122:125–32.CrossRefGoogle Scholar
  70. 70.
    Richards KA, Fukai K, Oiso N, et al. A novel KIT mutation results in piebaldism with progressive depigmentation. J Am Acad Dermatol. 2001;44:288–92.PubMedCrossRefGoogle Scholar
  71. 71.
    Jimbow K, Fitzpatrick TB, Szabo G, et al. Congenital circumscribed hypomelanosis: a characterization based on electron microscopy study of tuberous sclerosis, nevus depigmentosus and piebaldism. J Invest Dermatol. 1975;64:50–62.PubMedCrossRefGoogle Scholar
  72. 72.
    Falabella R, Barona M, Escobar C, et al. Surgical combination therapy for vitiligo and piebaldism. Dermatol Surg. 1995;21:852–7.PubMedCrossRefGoogle Scholar
  73. 73.
    Njoo MD, Nieuweboer-Krobotova L, Westerhof W. Repigmentation of leucodermic defects in piebaldism by dermabrasion and thin split-thickness skin grafting in combination with minigrafting. Br J Dermatol. 1998;139:829–33.PubMedCrossRefGoogle Scholar
  74. 74.
    Guerra L, Primavera G, Raskovic D, et al. Permanent repigmentation of piebaldism by erbium: YAG laser and autologous cultured epidermis. Br J Dermatol. 2004;150:715–21.PubMedCrossRefGoogle Scholar
  75. 75.
    Kovac S. Vitiligo. J Am Acad Dermatol. 1998;38:647–66.CrossRefGoogle Scholar
  76. 76.
    Kent G, Al’Abadie M. Psychologic effects of vitiligo: a critical incident analysis. J Am Acad Dermatol. 1996;35(6):895–8.PubMedCrossRefGoogle Scholar
  77. 77.
    Halder RM, Chappell JL. Vitiligo update. Semin Cutan Med Surg. 2009;28(2):86–92.PubMedCrossRefGoogle Scholar
  78. 78.
    Halder RM, Brooks HL. Medical therapies for vitiligo. Dermatol Ther. 2001;14:1–6.CrossRefGoogle Scholar
  79. 79.
    Boisseau-Garsaud AM, Garsaud P, Calès-Quist D, Hélénon R, Quénéhervé C, Claire RC. Epidemiology of vitiligo in the French West Indies (Isle of Martinique). Int J Dermatol. 2000;39(1):18–20.PubMedCrossRefGoogle Scholar
  80. 80.
    Falabella R, Barona M, Escobar C, Borrero I, Arrunategui A. Surgical combination therapy for vitiligo and piebaldism. Dermatol Surg. 1995;21(10):852–7.PubMedCrossRefGoogle Scholar
  81. 81.
    Nordlund JJ, Ortonne J. The normal color of human skin. In: Nordlund JJ, Boissy RE, Hearing VJ, King RA, Ortonne J, editors. The pigmentary system. Physiology and pathophysiology. New York: Oxford University Press; 1988. p. 475–84.Google Scholar
  82. 82.
    Hann SK, Kim Y-S, Yoo JH, Chun YS. Clinical and histopathologic characteristics of trichrome vitiligo. J Am Acad Dermatol. 2000;42:589–96.PubMedGoogle Scholar
  83. 83.
    Falabella R. Surgical therapies for vitiligo. Clin Dermatol. 1997;15(6):927–39. Review.PubMedCrossRefGoogle Scholar
  84. 84.
    Grimes PE. Melasma. Etiologic and therapeutic considerations. Arch Dermatol. 1995;131(12):1453–7. Review.PubMedCrossRefGoogle Scholar
  85. 85.
    Halder RM, Young CM. New and emerging therapies for vitiligo. Dermatol Clin. 2000;18(1): 79–89.PubMedCrossRefGoogle Scholar
  86. 86.
    Vitiligo JK. Therapeutic advances. Dermatol Clin. 1998;16(2):399–407.CrossRefGoogle Scholar
  87. 87.
    Scherschun L, Kim JJ, Lim HW. Narrow-band ultraviolet B is a useful and well-tolerated treatment for vitiligo. J Am Acad Dermatol. 2001;44(6):999–1003.PubMedCrossRefGoogle Scholar
  88. 88.
    Spencer JM, Nossa R, Ajmeri J. Treatment of vitiligo with the 30-nm excimer laser: a pilot study. J Am Acad Dermatol. 2002;46(5):727–31.PubMedCrossRefGoogle Scholar
  89. 89.
    Westerhof W, Nieuweboer-Krobotova L. Treatment of vitiligo with UVB radiation vs topical psoralen plus UVA. Arch Dermatol. 1997;133(12):1525–8.PubMedCrossRefGoogle Scholar
  90. 90.
    Passeron T, Ortonne JP. Use of the 308-nm excimer laser for psoriasis and vitiligo. Clin Dermatol. 2006;24:33–42.PubMedCrossRefGoogle Scholar
  91. 91.
    Ortonne JP, Passeron T. Melanin pigmentary disorders: treatment update. Dermatol Clin. 2005;23:209–26.PubMedCrossRefGoogle Scholar
  92. 92.
    Scherschun L, Kim JJ, Lim HW. Narrow-band ultraviolet B is a useful and well-tolerated treatment for vitiligo. J Am Acad Dermatol. 2001;44:999–1003.PubMedCrossRefGoogle Scholar
  93. 93.
    Scherschun L, Kim JJ, Lim H. Narrow-band UVB is a useful and well-tolerated treatment for vitiligo. J Am Acad Dermatol. 2001;44:999–1003.PubMedCrossRefGoogle Scholar
  94. 94.
    Arrunátegui A, Arroyo C, Garcia L, Covelli C, Escobar C, Carrascal E, Falabella R. Melanocyte reservoir in vitiligo. Int J Dermatol. 1994;33(7):484–7.PubMedCrossRefGoogle Scholar
  95. 95.
    Halder RM, Grimes PE, McLaurin CI, Kress MA, Kenney Jr JA. Incidence of common dermatoses in a predominantly black dermatologic practice. Cutis. 1983;32(4):388–90.PubMedGoogle Scholar
  96. 96.
    Halder RM. Topical PUVA therapy for vitiligo. Dermatol Nurs. 1991;3(3):178–80, 98.PubMedGoogle Scholar
  97. 97.
    Halder RM, Taliaferro SJ. Vitiligo. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest B, Paller A, Lefell D, editors. Fitzpatrick’s dermatology in general medicine. 7th ed. New York: McGraw-Hill; 2008.Google Scholar
  98. 98.
    Bose SK. Modified Thiersch grafting in stable vitiligo. J Dermatol. 1996;23(5):362–4.PubMedGoogle Scholar
  99. 99.
    Mosher DB, Parrish JA, Fitzpatrick TB. Monobenzylether of hydroquinone. A retrospective study of treatment of 18 vitiligo patients and a review of the literature. Br J Dermatol. 1977;77(97):669–79.CrossRefGoogle Scholar
  100. 100.
    Thissen M, Westerhof W. Laser treatment for further depigmentation in vitiligo. Int J Dermatol. 1997;36:386–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Dermatology and PathologyHoward University College of MedicineWashingtonUSA
  2. 2.Department of DermatologyHoward University College of MedicineWashingtonUSA

Personalised recommendations